Introduction: Lower respiratory tract infections (LRTIs) are a leading cause of mortality in sub-Saharan Africa. Triaging identifies patients at high risk of death, but laboratory tests proposed for use in severity-of-illness scores are not readily available, limiting their clinical use. Our objective was to determine whether baseline characteristics in hospitalized participants with LRTI predicted increased risk of death.
INTRODUCTION
Despite current advances in diagnostic techniques, improved treatment algorithms, and improved intensive care, 1,2 lower respiratory tract infections (LRTIs) remain a major cause of mortality globally. 3 Establishing the severity of disease and identifying specific pathogens causing infection is critical in guiding treatment of hospitalized patients with suspected LRTI. Severity of LRTI may be assessed using validated severity-of-illness scores, [4] [5] [6] whereas specific pathogens causing LRTI can be identified using conventional microbiological tests (sputum gram stain and bacterial cultures), serological tests, or novel molecular tests. 7 Despite the wide array of tests available, pathogens are identified in only 14%-40% patients with LRTI. 7, 8 For this reason, empiric antibiotic treatment for LRTI is justifiable pending results of bacteriological studies.
Most studies predicting outcomes of patients with LRTI and using severity-of-illness scores have been performed in HIV-negative participants. 9, 10 The prognosis of HIV-positive patients with LRTI may be poor due to the HIV-related immunosuppression that leads to increased susceptibility to recurrent and multiple coinfections, but there are only a few studies addressing this. In one study by Cordero et al, 11 shock, a CD4 count ,100 cells/mL, pleural effusions, cavitary disease, and multilobar infiltrates were identified as poor prognostic markers in participants with HIV infection and bacterial pneumonia.
In sub-Saharan Africa, which has a high burden of HIV and LRTI, 3 tests for diagnosing LRTI and for triaging patients with LRTI using severity-of-illness scores are rare. Vital signs and simple laboratory tests may therefore be more practical for initial patient assessment in urgent care. We have previously studied predictors of mortality in HIVpositive participants with pneumonia and attributed the increased mortality to delays in tuberculosis (TB) diagnosis 12 and severe disease. 13, 14 At the time of the current study, there was a noticeable shortening in the turn-around time for TB diagnosis due to the routine use of Xpert MTB/ RIF testing.
In this study of HIV-positive and HIV-negative participants, we determined whether baseline patient characteristics and vital signs identified adults with pneumonia at increased risk of death within 2 months of hospitalization. We also compared mortality and clinical predictors of mortality in HIV-positive and HIV-negative participants. Baseline characteristics associated with increased risk of mortality would identify a population of patients that could benefit from early and targeted interventions to improve clinical outcomes in LRTI.
METHODS

Population and Study Design
We present a secondary analysis of a prospective cohort study, the Mulago Inpatient Non-invasive Diagnosis-International HIV-associated Opportunistic Pneumonias (MIND-IHOP) Study. Adult patients ($18 years) with LRTI and cough of any duration who consented for the study underwent a standardized evaluation for pneumonia as described previously. 12, 13 This included an administered questionnaire on history, measured vital signs, physical examination related to respiratory disease, and assessment of their functional status (ie, whether they were ambulatory . or #50% of the day and what activities they were capable of performing). Additional investigations included HIV serology, CD4 cell counts (for HIV-positive patients), chest radiography, and sputum examination by microscopy [2 sputa for acid-fast bacilli (AFB)], sputum mycobacterial cultures [Lowenstein-Jensen and liquid culture (mycobacterial growth indicator tube)], and a single Xpert MTB/RIF. Patients who were HIV-positive, AFB sputum smear-negative (SS2), and Xpert-negative (Xpert2) underwent bronchoscopy if clinically indicated. During bronchoscopy, a diagnosis of pulmonary Kaposi sarcoma (pKS) was made on visualization of typical Kaposi sarcoma lesions in the endobronchial tree. We performed bronchoalveolar lavage and sent samples to be analyzed for Pneumocystis jirovecii using a modified Giemsa staining method as well as for AFB and mycobacterial cultures (LowensteinJensen and mycobacterial growth indicator tube).
All participants with presumed pneumonia received empiric treatment with antibiotics for 7-10 days unless an alternative diagnosis was made. Additional therapy with intravenous fluids and supplemental oxygen were administered as was clinically indicated.
Participants who improved on the above treatment were discharged and given an appointment for review by the study team 2 months after the date of their enrollment into the study. The 2-month follow-up was performed in person or by telephone (if the study participant was unable to come to the clinic). The purpose of the 2-month appointment was 3-fold (1) to assess vital status; (2) to assess clinical response to treatment; and (3) to provide results of pending diagnostic tests (eg, mycobacterial culture results) and appropriate treatment for those who were unable to be contacted earlier.
Study Outcomes
Study outcomes included participant vital status at hospital discharge and at 2 months from the date of enrollment into the study (alive or dead). Participants who failed to return for follow-up and were unreachable by phone after 16 attempts over an 8-week period were deemed lost to follow-up.
Statistical Analysis
We summarized baseline characteristics and vital sign measurements using medians with interquartile range (IQR) for continuous variables or percentages with 95% confidence intervals (CIs) for categorical variables. Continuous variables were categorized using clinically relevant cutoffs. The primary outcome was all-cause mortality at 2 months of follow-up, and the primary predictors were age (in years), sex, smoking status, HIV serostatus, functional status, 15 and danger signs [axillary temperatures, heart rate (HR), respiratory rate (RR), and oxygen saturation] 16 . Secondary predictors included CD4 counts and the use of antiretroviral therapy (ART) for the HIV-positive participants. We assessed strength of associations between clinical characteristics and mortality at 2 months using x 2 tests for categorical variables, t tests or rank sum tests for continuous variables (whether or not they were normally distributed, respectively), odds ratios, and 95% CIs. We stratified mortality analyses by TB status, HIV serostatus, and CD4 count strata (if HIV-positive), and history of empiric TB treatment. Variables that had a P-value of ,0.2 at bivariate analysis were included in a multivariable model using multiple logistic regression to identify variables that independently predicted mortality.
Ethical Approval
Ethical approval was obtained from the Makerere University School of Medicine Research and Ethics Committee, the University of California San Francisco Committee on Human Research, and the Uganda National Council for Science and Technology. All participants provided written informed consent.
RESULTS
Patient Characteristics
Of 2297 participants enrolled between April 11, 2011, and September 2, 2015, 1887 (82.2%) had 2-month follow-up information. Of these 1887 participants, 372 (19.7%) had died by 2 months of follow-up; 138 (37.1%) had died during hospitalization and the median duration of hospitalization was short, 3 days (IQR, 1-5 days). The median age of study participants was 34.3 years (IQR, 28.0-43.3 years), and 978 (51.8%) were men. The majority 1192 (63.2%) were HIVpositive with a median CD4 count of 81 cells/mL (IQR, 21-226 cells/mL). One-third (388/1192) of the HIV-positive participants were taking ART at admission. The median duration of cough was 4 weeks (IQR, 2-10 weeks), and 1376 (72.9%) had received antibiotics before hospitalization. The participants with complete data had similar baseline characteristics to those who had missing data except that the former were younger, had a higher temperature, and had a larger proportion of people who were bedridden (Table 1 , Supplemental Digital Content, http://links.lww.com/QAI/B215).
Patient Outcomes
Two hundred (10.6%) participants had severe hypoxemia with an oxygen saturation ,90% while breathing room air, and 1287 (68.2%) had one or more danger signs (pulse .120/min, RR .30/min, and temperature .39°C) present. A total of 711 (37.7%) participants had a microbiologically confirmed diagnosis; 670 (35.5%) had TB, 26 (1.4%) had pKS, and 15 (0.8%) had Pneumocystis pneumonia (PcP). Of 288 patients who underwent bronchoscopy, 55 (19.1%) died during follow-up. At 2 months of follow-up, only 388/920 (42.2%) of the HIV-positive participants were on ART. There was a significant difference among participants who died and who were alive at 2 months in respect to HIV serostatus, pKS and PcP diagnosis, and presence of danger signs (Table 1) .
Mortality by HIV Status
The HIV-positive participants differed from the HIVnegative participants. In addition to being younger, a greater proportion of HIV-seropositive participants hospitalized with LRTI was female, did not smoke, had a diagnosis of TB, had danger signs, or were bed-bound compared with those who were HIV-negative Table 2 ). In addition, there was a significantly higher( mortality among the HIV-positive participants than the HIV-negative participants both during hospitalization [99 (8.3%) in HIV-positive vs. 32 (4.6%) in HIV-negative, P , 0.0001] and at 2 months of follow-up [272 (22.8%) HIVpositive vs. 100 (14.4%) in HIV-negative, P , 0.0001].
Predictors of Mortality
Several baseline patient characteristics and vital signs were associated with increased 2-month mortality. In the univariate analysis (Table 3) , temperature ,35.5°C, temperature 37.2°C-39°C, HR .120/min, and RR .30/min were associated with increased mortality. In addition, oxygen saturation ,90%, being bed-bound, and being HIV-positive were also associated with increased mortality. In the multivariable analysis, temperature ,35.5°C [adjusted odds ratio (aOR) = 1.77, 95% CI: 1.20 to 2.60; P = 0.004], HR .120/ min (aOR = 1.82, 95% CI: 1.37 to 2.43; P , 0.0001), oxygen saturation ,90% (aOR = 2.74, 95% CI: 1.97 to 3.81; P , 0.0001), being bed-bound (aOR = 1.88, 95% CI: 1.47 to 2.41; P , 0.0001), and being HIV-positive (aOR = 1.49, 95% CI: 1.14 to 1.94; P = 0.003) were independently associated with increased mortality at 2 months.
Predictors of Mortality by HIV Status
When stratified by HIV status, participants who were HIV-seropositive had a higher odds of dying if they had a HR .120/min (aOR = 1.54, 95% CI: 1.10 to 2.15; P = 20.01) compared to those with a HR #120/min. Having an oxygen saturation ,90% on room air was associated with twice the odds of death (aOR = 2.56, 95% CI: 1.71 to 3.84; P , 0.0001) compared with oxygen saturation .90%. Participants who were bed-bound had a higher odds of death (aOR = 1.48, 95% CI: 1.09 to 2.00; P = 0.01) than those who were not. Finally, participants with CD4 counts 50-100 cells/mL had twice the odds of death (aOR = 2.03, 95% CI: 1.24 to 3.35; P = 0.005), and participants with ,50 cells/mL had thrice the odds of death (aOR = 3.42, 95% CI: 2.29 to 5.11; P , 0.0001) than those with CD4 counts .200 cells/mL (Table 4) . For participants who were HIV-seronegative, the following variables were independently predictive of mortality:
age .40 years (aOR = 2.04, 95% CI: 1.18 to 3.53; P = 0.01), body temperature ,35.5°C (aOR = 2.17, 95% CI: 1.08 to 4.37; P = 0.03), HR .120/min (aOR = 2.13, 95% CI: 1.16 to 3.92; P = 0.02), oxygen saturation ,90% (aOR = 2.75, 95% CI: 1.48 to 5.10; P = 0.001), and being bed-bound (aOR = 2.37, 95% CI: 1.49 to 3.75; P , 0.001) ( Table 5) .
Mortality During and after Hospitalization
The independent predictors of in-hospital mortality were HR .120/min (aOR = 1.61, 95% CI: 1.06 to 2.46; P , 0.03), oxygen saturation ,90% (aOR = 3.25, 95% CI: 2.12 to 5.00; P , 0.0001), and being bed-bound (aOR = 4.36, 95% CI: 2.70 to 7.04; P , 0.0001) ( Table 2 , Supplemental Digital Content, http://links.lww.com/QAI/B215). After discharge and during the posthospitalization study period, the following predictors were independently associated with mortality: temperature .39°C was associated with a 58% odds of reduction in mortality (aOR = 0.42, 95% CI: 0.19 to 0.92; P = 0.03). HR .120/min (aOR = 1.88, 95% CI: 1.33 to 2.65; P , 0.0001), oxygen saturation ,90% [aOR = 2.09, 95% (aOR = 1.34, 95% CI: 1.34 to 3.75; P , 0.001)], and being HIVseropositive (aOR = 1.49, 95% CI: 1.08 to 2.05; P = 0.015) were all independent risk factors for mortality (Table 3 , Supplemental Digital Content, http://links.lww.com/QAI/B215).
Effect of Empiric TB Treatment on Mortality
Of all the study participants, 1170 (62.0%) were both sputum smear-negative and Xpert-negative (SS2 and Xpert2) for TB, and 148 (12.6%) of these had positive sputum cultures for TB. Sixty-two participants (5.2%) who were SS2 and Xpert2 were empirically treated for TB; of these, only 17 (27.4%) had culture-confirmed TB at followup. Most participants (45, 73%) who were empirically treated had danger signs. At multivariable analysis, after adjusting for age, temperature, HR, RR, oxygen saturation, functional status, HIV serostatus, and functional status, empiric TB treatment was associated with a nonsignificant trend toward a reduction in mortality among participants with presumed 
DISCUSSION
In this study of HIV-positive and HIV-negative adult patients with LRTI who underwent standardized evaluation for pneumonia and were followed for 2 months, we determined whether baseline patient characteristics and vital signs identified adults with pneumonia at increased risk of death within 2 months of hospitalization. Despite detailed investigations to identify and appropriately treat respiratory pathogens in hospitalized patients with LRTI, mortality at 2 months remains high, at nearly 20%. We show that baseline patient characteristics and vital signs identified adults with LRTI at increased risk of death. Specifically, vital signs (temperature ,35.5°C, HR .120/min, and oxygen saturation ,90% on room air) and baseline characteristics (being bedbound and HIV-positive) independently predict increased mortality within 2 months of hospitalization among patients with LRTI. These variables may be used to triage patients with LRTI at increased risk of death. Routinely measuring vital signs that are predictive of mortality may be useful for identifying hospitalized individuals with lower respiratory infection who are at risk of sepsis. Recently, newer scores have been derived to improve prediction of mortality in the emergency care unit and duration of intensive care unit (ICU) stay. These include the sequential organ failure assessment (SOFA) and the quick SOFA. 17 They have been principally validated in high-income settings. The quick SOFA uses simple clinical criteria (altered mentation, systolic blood pressure of 100 mm Hg or lower, or RR of at least 22 breaths per minute) and has a higher predictive value for mortality outside the ICU. Until these scores are widely validated in diverse populations in both high-income and low-income settings, early diagnosis of sepsis using easily measurable clinical parameters is important. Second, mortality is related to hypoxemia, and this has been observed in local 13, 14 and regional studies. 18, 19 This may be due to acute hypoxemic respiratory failure complicating pneumonia. Acute hypoxemic respiratory failure has been associated with increased mortality, especially where facilities for mechanical ventilation and oxygenation are limited. 19 Similar to our study, hypoxemia was reported to be an independent predictor of the clinical severity of pneumonia and is associated with an increased risk of death from severe sepsis. 20 When combined with validated severity-of-illness scores, hypoxemia leads to an improvement in their predictive value. 21, 22 Oxygen is essential for management of patients who have severe pneumonia and are in respiratory failure. In usual care, oxygen is delivered by nasal prongs or by face mask, but this may be inadequate and further management in an ICU may be needed. There are very few hospitals in lowincome settings that have capacity to set-up and efficiently run an ICU. Innovative ways of oxygen delivery to pneumonia patients outside the ICU like using noninvasive ventilation 23 and high-flow nasal cannulas 24 need to be urgently explored.
Third, advanced HIV-related immunosuppression remains an important predictor of mortality in settings with a high HIV burden. This finding is not entirely surprising because advanced HIV-related immunosuppression is associated with opportunistic diseases such as PcP and pKS, which contribute to the increase in mortality due to LRTI. 25, 26 Notably, only one-third of the HIV-positive participants in our study was on ART at hospitalization, a proportion that did not substantially change at 2 months. This shows the presence of important barriers to ART access. Most ART is provided in ambulatory settings where these patients are referred on discharge from hospital. A deliberate action to initiate these patients on ART during hospitalization or to follow-up and ensure they are initiated on ART in sites to which they are referred for care is crucial.
Finally, failure to determine the cause of LRTI in most study participants may contribute to the persisting high mortality due to pneumonia because many participants did not receive targeted therapy for LRTI. In addition, antimicrobial resistance (AMR) to commonly used antibiotics was not determined. There have been few studies on AMR for causative organisms for pneumonia in this setting, but a recent report on AMR of isolates from blood cultures in this setting revealed high-level resistance to commonly used antibiotics. 27 This may be an additional cause of poor treatment outcomes. These should be considered in prospective studies of LRTI. Despite exhaustive testing for causes of LRTI, a minority of study participants have confirmed diagnoses even in settings with better resources. 8, 28 Molecular testing has shown capacity to detect pathogens and resistance mutations despite previous antibiotic use, but these methods need to be further validated to establish proper standards for LRTI testing. 28, 29 Our study had several limitations. We had a loss to followup of 21%, which is not unusual in a mobile urban population where patients seeking treatment at a tertiary urban center return to their rural homes after clinical improvement or worsening. A proportion of these missing participants could have died. This could have led to an underestimate of the mortality and the predictive role of age category, a high temperature, and being bed-ridden on mortality. Second, the findings of this study in a tertiary care center can only be generalized to similar settings because these participants may represent a severely ill population not frequently found at lower levels of health care. Third, our findings are based only on parameters measured at the time of hospitalization. Kolditz et al 30 demonstrated that participants who do not have an immediate need for mechanical ventilation or vasopressor support at admission but deteriorated during hospitalization are associated with higher mortality than those who have abnormalities of vital signs at admission. Additional measurement of vital signs during hospitalization may better define the response of participants to antibiotic treatment, and better define their prognosis. Fourth, we did not measure the systolic blood pressure in all participants and were not able to assess the predictive role of this on outcomes of study participants as has been noted in the newer predictor scores. 17 Fifth, despite a better than standard workup for LRTI in a lowincome setting, only 38% participants had a confirmed diagnosis for a respiratory pathogen. It was not possible to confirm presence of bacterial, viral, or other pathogens using this approach. Finally, hypoxia was a major risk factor for mortality, but the study was not able to provide data on the usage or availability throughout the study.
In conclusion, vital signs and some patient baseline characteristics identify hospitalized patients with LRTI at high risk of death who need urgent medical care and close monitoring. Quality improvement initiatives that promote routine collection and use of vital signs for clinical decision making and innovative techniques for oxygen delivery should be optimized for management of patients with pneumonia. Providing adequate oxygen, judicious intravenous fluids, and early antiretroviral therapy (in people living with HIV/AIDS) can be life-saving in hospitalized patients with LRTI.
